About Us

Contact Us

Home About Us Product News Order Career Contact


           APIs&Intermediates Chemicals of Shanghai APIs Chemical Co., Ltd 


Product Indentification

Name:   AZD 8055
Synonyms:   [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol
CAS Registry Number:   1009298-09-2
Molecular Formula:   C25H31N5O4
Molecular Weight:    465.54
Molecular Structure:  




                   In stock!  5g,10g,15g! BULK!



                   Appearance:  Yellow solid






                   For Research Used Only






Related mTOR Inhibitors:



         AZD8055|1009298-09-2                                                    Deforolimus|572924-54-0        


         NVP-BEZ 235|915019-65-7                                                               Everolimus|159351-69-6


         GSK1059615|958852-01-1                                                               KU-0063794|938440-64-3                           


         PI-103|371935-74-9                                                                           PP242|1092351-67-1


          PKI-587|1197160-78-3                                                                      Rapamycin|53123-88-9




         Temsirolimus|162635-04-3                                                               WYE-35|1062169-56-5





Related pages:

     Search AZD 8055 in google
     Search CAS 1009298-09-2    in google
     Search C25H31N5O4 in google


Related information:


       AZD8055 is an ATP-competitive inhibitor of mammalian target of rapamycin (mTOR) that forms two multiprotein  complexes, mTORC1 and mTORC2, and negatively regulates autophagy. AZD8055, a novel ATP-competitive inhibitor of mTOR kinase activity, with an IC50 of 0.8 nmol/L. AZD8055 showed excellent selectivity (∼1,000-fold) against all class I phosphatidylinositol 3-kinase (PI3K) isoforms and other members of the PI3K-like kinase family. Furthermore, there was no significant activity against a panel of 260 kinases at concentrations up to 10 μmol/L. AZD8055 inhibits the phosphorylation of mTORC1 substrates p70S6K and 4E-BP1 as well as phosphorylation of the mTORC2 substrate AKT and downstream proteins. The rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1 were fully inhibited by AZD8055, resulting in significant inhibition of cap-dependent translation. In vitro, AZD8055 potently inhibits proliferation and induces autophagy in H838 and A549 cells. In vivo, AZD8055 induces a dose-dependent pharmacodynamic effect on phosphorylated S6 and phosphorylated AKT at plasma concentrations leading to tumor growth inhibition. Notably, AZD8055 results in significant growth inhibition and/or regression in xenografts, representing a broad range of human tumor types. AZD8055 is currently in phase I clinical trials. Cancer Res; 70(1); 28898




Home About Us Product News Order Career Contact
 Copyright @ 2010-2011 APIs All rights reserved